GLP-1s & Hip Fracture Fixation: Lower Revision Risk Found in Diabetics

New research presented at the American Academy of Orthopaedic Surgeons Annual Meeting suggests that GLP-1 receptor agonists, a class of medications increasingly used for type 2 diabetes and weight management, do not appear to increase short-term medical or surgical complications in patients undergoing hip fracture fixation. While the study focused on outcomes following femoral neck fracture, the findings offer a reassuring signal as more patients present for orthopedic procedures while on these medications. The research, led by McKenna W. Box, MD, at the Medical City Denton Orthopedic Surgery Residency program in Texas, also indicated a potential benefit: a lower risk of revision surgery from fixation to total hip arthroplasty among patients taking GLP-1 agonists.

Understanding GLP-1 Agonists and Hip Fracture Care

GLP-1 agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), work by mimicking the effects of a natural hormone that regulates blood sugar and appetite. Their growing popularity has led to increased use among individuals with type 2 diabetes and obesity, and a larger number of patients undergoing surgical procedures while on these medications. Recent studies have also explored the impact of GLP-1s on other conditions, like diabetic retinopathy.

Hip fractures, particularly femoral neck fractures, are a significant health concern, especially among older adults. Fixation, whether through open reduction and internal fixation or closed reduction and percutaneous pinning, aims to stabilize the fracture and allow for healing. Though, concerns arose regarding potential complications in patients taking GLP-1 agonists, including increased risk of aspiration pneumonitis (inflammation of the lungs caused by inhaling foreign material) and delayed wound healing.

Study Design and Key Findings

To address these concerns, Dr. Box and colleagues conducted a retrospective analysis of 112 patients with type 2 diabetes who underwent fixation for femoral neck fracture. They employed a propensity score matching technique, carefully balancing characteristics like age, sex, BMI, smoking status, and overall health burden (Elixhauser comorbidity index) between patients who were and were not taking GLP-1 agonists. This approach helps to minimize bias and ensure a more accurate comparison.

The primary outcomes assessed were aspiration pneumonitis during the initial hospitalization and surgical complications within one year. Secondary outcomes included overall medical complications, in-hospital mortality, and discharge to hospice. The researchers found no significant difference in aspiration rates between the two groups. Most surgical complications were similar. However, a statistically significant finding emerged: patients on GLP-1 agonists had a lower risk of requiring revision surgery, specifically conversion from fixation to total hip arthroplasty.

Interpreting the Results: What Does This Mean?

The absence of increased short-term complications is encouraging, suggesting that continuing GLP-1 agonists around the time of hip fracture fixation does not necessarily pose an elevated risk to patients. The observed reduction in revision surgery is particularly noteworthy, although further investigation is needed to understand the underlying mechanisms. It’s possible that the metabolic benefits of GLP-1 agonists, such as improved glucose control and potential effects on bone health, may contribute to better healing and reduced need for more extensive surgery.

It’s crucial to acknowledge the study’s limitations. The retrospective design, while practical, is susceptible to confounding factors that may not have been fully accounted for. The sample size of 112 patients is relatively small, which limits the statistical power to detect subtle differences. The study focused specifically on femoral neck fractures. the findings may not be generalizable to other types of fractures or surgical procedures. As Dr. Box noted, larger studies with more diverse patient populations are needed to confirm these results and explore the long-term effects of GLP-1 agonists on orthopedic outcomes.

GLP-1s and Opioid Use: A Complex Relationship

While this study focused on orthopedic outcomes, it’s important to note that GLP-1 agonists have also been linked to changes in opioid prescription patterns. Research from Hospital for Special Surgery indicates that patients taking GLP-1s may refill opioid prescriptions more frequently than those not on the medication. The reasons for this are complex and may include blunted responses to pain medication in individuals with metabolic disease, as well as the timing of restarting GLP-1s after surgery. Rapid weight loss associated with GLP-1 use could also play a role, potentially increasing the risk of postoperative infection.

Safety Concerns and Compounded GLP-1s

The increasing demand for GLP-1 agonists has led to shortages and the emergence of non-FDA-approved, compounded versions of these medications. Medical organizations have issued warnings about the safety risks associated with these unregulated alternatives, which lack the rigorous testing and oversight of FDA-approved drugs. The FDA is taking steps to ban compounded forms as shortages ease, emphasizing the importance of using only legitimate medications prescribed by a healthcare professional.

What Comes Next: Ongoing Research and Clinical Practice

The findings from Dr. Box’s study underscore the need for ongoing research to better understand the impact of GLP-1 agonists on orthopedic outcomes. Future studies should focus on larger, more diverse patient populations, longer follow-up periods, and exploration of the mechanisms underlying the observed effects. Clinicians should continue to carefully assess patients taking GLP-1 agonists before and after orthopedic surgery, gathering information on medication duration and dosage. A collaborative approach, involving orthopedic surgeons, endocrinologists, and primary care physicians, is essential to optimize patient care and ensure safe and effective treatment.

As GLP-1 agonists become increasingly prevalent, staying informed about their potential effects on various aspects of health, including surgical outcomes, will be crucial for healthcare professionals and patients alike. Continued surveillance and research will help refine clinical guidelines and ensure that these medications are used safely and effectively to improve patient well-being.